SS Innovations International (NASDAQ: SSII) has supported the launch of Sri Lanka's first robotic cardiac surgery program at Kings Hospital Colombo, using the SSi Mantra 3.0 surgical robotic system. The program began with a robotic-assisted left internal mammary artery (LIMA) takedown performed by Dr. Sudhir Srivastava, founder and chairman of SS Innovations, alongside Kings Hospital cardiothoracic surgeon Dr. Rajitha DeSilva. This development was highlighted in a recent company video describing the program's early activity.
According to the video, Kings Hospital has completed more than 25 robotic procedures in just three weeks, demonstrating rapid adoption and proficiency with the SSi Mantra system. The successful introduction of robotic cardiac surgery in Sri Lanka represents a significant milestone for the country's healthcare sector, which previously relied on traditional open-heart surgery for cardiac interventions. Robotic-assisted procedures offer potential benefits such as smaller incisions, reduced pain, faster recovery times, and improved precision for surgeons.
SS Innovations reported 224 cumulative SSi Mantra installations across 12 countries at the end of the second quarter. The company's second-quarter revenue reached $13.9 million, while robotic procedures increased 143% year over year to 2,528, pointing to rising utilization of the company's installed base. These figures underscore the growing demand for robotic surgical solutions globally and SS Innovations' expanding market presence.
The next major corporate milestone is regulatory expansion, with SS Innovations pursuing U.S. FDA clearance and European CE marking for the SSi Mantra system. Achieving these certifications would allow the company to enter two of the largest and most lucrative healthcare markets in the world, potentially accelerating revenue growth and further legitimizing its technology on a global scale. The success in Sri Lanka adds to the company's credibility as it seeks to compete with established players in the surgical robotics field.
The launch also has implications for medical tourism in Sri Lanka, as advanced robotic cardiac surgery could attract patients from neighboring countries seeking high-quality, minimally invasive care. Kings Hospital Colombo's ability to perform such procedures positions it as a regional leader in cardiac care. For SS Innovations, this program serves as a showcase for the SSi Mantra 3.0's capabilities in complex cardiac procedures, which could drive adoption in other emerging markets.
Investors and industry observers will be watching closely to see if SS Innovations can maintain its momentum and secure the necessary regulatory approvals. The company's forward-looking statements note risks and uncertainties that could affect actual results, including factors beyond management's control. Nonetheless, the successful launch in Sri Lanka and the company's strong procedural growth suggest that robotic surgery is gaining traction worldwide.
For more information, see the full terms of use and disclaimers on the InvestorBrandNetwork website: https://IBN.ai/Disclaimer. The latest news and updates relating to SSII are available in the company's newsroom at https://ibn.fm/SSII.
